Effect of cyclic nucleotides and phosphodiesterase inhibition on morphine tolerance and physical dependence.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D000242:Cyclic AMP / Q000494:pharmacology*; D006152:Cyclic GMP / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D004361:Drug Tolerance; D006801:Humans; D051379:Mice; D009020:Morphine / Q000008:administration & dosage; D009270:Naloxone / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors; D013375:Substance Withdrawal Syndrome / Q000378:metabolism; D019966:Substance-Related Disorders / Q000378:metabolism*; D013806:Theophylline / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D010726:Phosphodiesterase Inhibitors; D009270:Naloxone; D009020:Morphine; D003513:Cycloheximide; D013806:Theophylline; D000242:Cyclic AMP; D006152:Cyclic GMP